Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer
Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiati...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/1715064 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850179577204178944 |
|---|---|
| author | Iwona Wertel Dorota Suszczyk Anna Pawłowska Monika Bilska Agata Chudzik Wiktoria Skiba Roman Paduch Jan Kotarski |
| author_facet | Iwona Wertel Dorota Suszczyk Anna Pawłowska Monika Bilska Agata Chudzik Wiktoria Skiba Roman Paduch Jan Kotarski |
| author_sort | Iwona Wertel |
| collection | DOAJ |
| description | Ovarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiation between malignant and benign tumors, monitoring the progression of the disease, and identification of patients that will respond to implemented treatment. Our study is aimed at evaluating the profile of IL-6 in the plasma and peritoneal fluid (PF) of patients with various clinical manifestations of OC (n=78). We also examined the relationship between IL-6 and PD-L1/PD-L2 positive CD45+CD14+ inflammatory cell (MO/MA) levels in three OC environments (TME): peripheral blood (PB), PF, and tumor (TT) and their clinical and prognostic relevance in OC patients. The expression of PD-L1/PD-L2 molecules was analyzed by flow cytometry. The IL-6 levels were determined by ELISA. We found an elevated level of PD-L1/PD-L2 positive MO/MA in TT compared to PB (p<0.0001). Significantly higher (p<0.0001) levels of IL-6 were observed in PF of the OC patients than in the benign ovarian tumor group (n=31). Additionally, we found higher IL-6 levels in PF than in the plasma of the OC patients. Interestingly, accumulation of IL-6 was observed in PF of patients with low-differentiated OC and correlated with worse prognosis. Moreover, we observed correlations between the level of IL-6 and CD45+CD14+ cells and between CD45+CD14+PD-L1+ cells and the IL-6 level in PF. For the first time, we discovered that the higher percentage of CD45+CD14+PD-L2+ cells in PF predicts better survival of OC patients. Our study suggests that CD45+CD14+PD-L2+ cells and IL-6 may be predictive biomarkers for OC patients. Understanding how the composition of TME changes during OC development and progression is a prerequisite for projecting new therapeutic strategies. Overall, further validation research is warranted. |
| format | Article |
| id | doaj-art-9c49a56718c14a598b5e19ec6d80d861 |
| institution | OA Journals |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-9c49a56718c14a598b5e19ec6d80d8612025-08-20T02:18:28ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/17150641715064Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian CancerIwona Wertel0Dorota Suszczyk1Anna Pawłowska2Monika Bilska3Agata Chudzik4Wiktoria Skiba5Roman Paduch6Jan Kotarski7Independent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandIndependent Public Clinical Hospital No. 1, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandIndependent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandStudents’ Scientific Association, Independent Laboratory of Cancer Diagnostics and Immunology, I Chair and Department of Gynecologic Oncology and Gynecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandDepartment of Virology and Immunology, Maria Curie-Skłodowska University, Akademicka 19, 20-033 Lublin, PolandI Chair and Department of Oncological Gynaecology and Gynaecology, Medical University of Lublin, Staszica 16, Lublin 20-081, PolandOvarian cancer (OC) is one of the deadliest gynecological cancers. Recent studies suggest a crucial role of inflammatory immune system cells in the progression and metastasis of OC. The understanding of inflammatory mechanisms is pivotal for the selection of a biomarker that allows the differentiation between malignant and benign tumors, monitoring the progression of the disease, and identification of patients that will respond to implemented treatment. Our study is aimed at evaluating the profile of IL-6 in the plasma and peritoneal fluid (PF) of patients with various clinical manifestations of OC (n=78). We also examined the relationship between IL-6 and PD-L1/PD-L2 positive CD45+CD14+ inflammatory cell (MO/MA) levels in three OC environments (TME): peripheral blood (PB), PF, and tumor (TT) and their clinical and prognostic relevance in OC patients. The expression of PD-L1/PD-L2 molecules was analyzed by flow cytometry. The IL-6 levels were determined by ELISA. We found an elevated level of PD-L1/PD-L2 positive MO/MA in TT compared to PB (p<0.0001). Significantly higher (p<0.0001) levels of IL-6 were observed in PF of the OC patients than in the benign ovarian tumor group (n=31). Additionally, we found higher IL-6 levels in PF than in the plasma of the OC patients. Interestingly, accumulation of IL-6 was observed in PF of patients with low-differentiated OC and correlated with worse prognosis. Moreover, we observed correlations between the level of IL-6 and CD45+CD14+ cells and between CD45+CD14+PD-L1+ cells and the IL-6 level in PF. For the first time, we discovered that the higher percentage of CD45+CD14+PD-L2+ cells in PF predicts better survival of OC patients. Our study suggests that CD45+CD14+PD-L2+ cells and IL-6 may be predictive biomarkers for OC patients. Understanding how the composition of TME changes during OC development and progression is a prerequisite for projecting new therapeutic strategies. Overall, further validation research is warranted.http://dx.doi.org/10.1155/2020/1715064 |
| spellingShingle | Iwona Wertel Dorota Suszczyk Anna Pawłowska Monika Bilska Agata Chudzik Wiktoria Skiba Roman Paduch Jan Kotarski Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer Journal of Immunology Research |
| title | Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer |
| title_full | Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer |
| title_fullStr | Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer |
| title_full_unstemmed | Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer |
| title_short | Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer |
| title_sort | prognostic and clinical value of interleukin 6 and cd45 cd14 inflammatory cells with pd l1 pd l2 expression in patients with different manifestation of ovarian cancer |
| url | http://dx.doi.org/10.1155/2020/1715064 |
| work_keys_str_mv | AT iwonawertel prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT dorotasuszczyk prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT annapawłowska prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT monikabilska prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT agatachudzik prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT wiktoriaskiba prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT romanpaduch prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer AT jankotarski prognosticandclinicalvalueofinterleukin6andcd45cd14inflammatorycellswithpdl1pdl2expressioninpatientswithdifferentmanifestationofovariancancer |